No added value of the methionine loading test in assessment for venous thrombosis and cardiovascular disease risk

Miranda B. A. J. Keijzer; Petra Verhoef; George F. Borm; Henk J. Blom; Martin den Heijer

doi:10.1160/TH05-07-0498

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2006; 95(02): 380-385
DOI: 10.1160/TH05-07-0498

New Technologies, Diagnostic Tools and Drugs

Schattauer GmbH

No added value of the methionine loading test in assessment for venous thrombosis and cardiovascular disease risk

Authors

Miranda B. A. J. Keijzer

¹Department of Endocrinology, Radboud University Nijmegen Medical Centre
Petra Verhoef

²Wageningen Centre for Food Sciences and Wageningen University, Division of Human Nutrition, Wageningen
George F. Borm

³Department of Epidemiology and Biostatistics
Henk J. Blom

⁴Laboratory of Paediatrics and Neurology, Radboud University Nijmegen Medical Centre, The Netherlands
Martin den Heijer

¹Department of Endocrinology, Radboud University Nijmegen Medical Centre

³Department of Epidemiology and Biostatistics

Abstract

Summary

Homocysteine isa risk factor for cardiovascular disease and venous thrombosis. Clinical guidelines differ in their recommendation whether or not to measure homocysteine after methionine loading. In this study, we investigated the added value of the methionine loading test next to fasting homocysteine levels for identifying subjects at risk for venous thrombosis or cardiovascular disease, using Receiver Operating Characteristic (ROC) curves.The analysis was performed in 185 patients with recurrent venous thrombosis, 130 patients with cardiovascular disease and 601 controls.The discriminatory power of the fasting homocysteine measurement alone for identifying subjects at risk of venous thrombosis expressed as the area under the ROC curve (AUC) was 0.61 (95%CI 0.56-0.66). Using both a fasting homocysteine measurement and a methionine loading test together yielded a similar AUC of 0.65 (95%CI 0.60-0.69), indicating no added value of methionine loading next to fasting homocysteine measurement in identifying subjects at risk for thrombosis. Similar results where found for cardiovascular disease, with anAUC of 0.62 (95%CI 0.57-0.67) for the fasting homocysteine measurement alone and an AUC of 0.62 (95%CI 0.57-0.67) for the combination of both the fasting and the postload homocysteine measurement. The methionine loading test has no added value next to measuring fasting homocysteine levels for identifying subjects at risk for venous thrombosis or cardiovascular disease and for that reason should not be used in clinical practice.

Keywords

Methionine loading test - hyperhomocysteinemia - homocysteine - venous thrombosis - ROC curve

Full Text

References

References
1 The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. JAMA 2002; 288: 2015-22.
2 den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis:a metaanalysis of published epidemiological studies. J Thromb Haemost 2005; 03: 292-9.
3 Refsum H, Smith AD, Ueland PM. et al. Facts and recommendations about total homocysteine determinations: An experts opinion. Clin Chem 2004; 50: 3-32.
4 Stanger O, Hermann W, Pietrzik K. et al. D.A.CH.Liga Homocysteine (German, Austrian and Swiss homocysteine society): Consensus paper on the rational clinical use of homocysteine, folic acid, and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 2003; 41: 1392-403.
5 Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases A statement for healthcare professionals from the Nutrition Committee American Heart Association. Circulation 1999; 99: 178-82.
6 The Netherlands Heart Foundation. [Guidelines Homocysteïne and Cardiovascular Disease]. Dutch. May 2001
7 Van der Griend R, Haas FJLM, Duran M. et al. Methionine loading test is necessary for detection of hyperhomocysteinemia. J Lab Clin Med 1998; 132: 67-72.
8 Bostom AG, Jacques PF, Nadeau MR. et al. Postmethionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from The NHLBI Family Heart Study. Atherosclerosis 1995; 116: 147-51.
9 Cattaneo M, Martinelli I, Mannucci PM. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis (letter). N Engl J Med 1996; 13: 974-75.
10 Graham IM, Daly LE, Refsum HM. et al. Plasma homocysteine as a risk factor for vascular disease The European Concerted Action Project. JAMA 1997; 277: 1775-81.
11 Fowler B, Sardharwalla IB, Robins AJ. The detection of heterozygotes for homocystinuria by oral loading with L-methionine. Biochem J 1971; 122: 23-4.
12 McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis 1975; 22: 215-27.
13 Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease A possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-82.
14 Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ. et al. Molecular genetic analysis in mild hyperhomocysteinemia:A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
15 Den Heijer M, Rosendaal FR, Blom HJ. et al. Hyperhomocysteinemia and venous thrombosis: a metaanalysis. Thromb Haemost 1998; 80: 874-7.
16 Keijzer MBAJ, den Heijer M, Blom HJ. et al. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolate reductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost 2002; 88: 723-8.
17 Boushey CJ, Beresford SAA, Omenn GS. et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
18 Den Heijer M, Blom HJ, Gerrits WBJ. et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?. Lancet 1995; 345: 882-5.
19 Verhoef P, Kok FJ, Kruyssen DA. et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 989-95.
20 Den Heijer M, Bos GMJ, Brouwer IA. et al. Variability of the methionine loading test: no effect of a low protein diet. Ann Clin Biochem 1996; 33: 551-4.
21 Te Poele-Pothoff MT, van den Berg M, Franken DG. et al. Three different methods for the determination of total homocysteine in plasma. Ann Clin Biochem 1995; 32: 218-20.
22 Pepe MS, Janes H, Longton G. et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004; 159: 882-90.
23 Den Heijer M, Te Poele-Potthof M, Blom HJ. Hyperhomocysteinemia : risk factor or consequence of venous thrombosis?. J Inherit Metab Dis. 2003 26. suppl 1.
24 Smulders YM. The (non-)sense of the methionine loading test for detecting hyperhomocysteinaemia. Neth J Med 2000; 57: 172-3.
25 Van de Laak MF, Grobbee DE, Van der Griend R. et al. A 2-step strategy to reduce the need for methionineloading tests to diagnose hyperhomocysteinemia. J Lab Clin Med 2003; 142: 121-7.
26 Marongiu F, Fenu L, Pisu G. et al. Hyperhomocysteinemia: could the post-methionine oral loading test sometimes be avoided?. Haematologica 2003; 88: 186-91.
27 Ubbink JB, Becker PJ, Delport R. et al Variability of post-methionine load plasma homocysteine assays. Clin Chim Acta 2003; 330: 111-9.
28 De Jonge R, Griffioen PH, van Zelst B. et al. Evaluation of a shorter methionine loading test. Clin Chem Lab Med 2004; 42: 1027-31.
29 Bostom AG, Roubenoff R, Dellaripa P. et al. Validation of abbreviated oral methionine-loading test. Clin Chem 1995; 41: 948-9.
30 Wald DS, Law M, Morris JK. The dose-response relation between serum homocysteine and cardiovascular disease: implications for treatment and screening. Eur J Cardiovasc Prevention Rehab 2004; 11: 250-3.